Currently, a variety of small molecules and peptides that target the p53-MDM2 interaction or pathways have been shown to inhibit tumor growth through sustained activation of p53 target gene(s), inducing cell cycle arrest and apoptosis, and/or by reducing the resistance of cancer cells to radiotherapy (Fig. 2). The gene discussed is TP53; the disease is cancer.